Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more
Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma over the standard of care in. | March 25, 2022
Major pharmaceutical firms are seeking to strike a balance between international opprobrium over Russia’s invasion of Ukraine and the needs of sick patients.
After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free